Skip to main content

TRIAMVEX

Generic: Triamcinolone Acetonide

Verified·Apr 23, 2026
NDC
73086-100
RxCUI
1014314
ICD-10 indication
L30.9

Affordability Check

How much will you actually pay for TRIAMVEX?

In 30 seconds, see every legitimate way to afford TRIAMVEX — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About TRIAMVEX

What is this medication? Kenalog-40 is a prescription corticosteroid medication that contains the active ingredient triamcinolone acetonide. It is primarily used to reduce inflammation in the body and to suppress an overactive immune system. This medication is often administered by a healthcare professional as an injection into a muscle, joint, or specific skin lesion depending on the condition being treated. By mimicking the effects of hormones naturally produced by the adrenal glands, it helps alleviate swelling, redness, and pain associated with various medical issues. This medication is prescribed for a wide range of conditions across different medical specialties. It is commonly used to manage severe allergic reactions, asthma, and chronic inflammatory disorders like rheumatoid arthritis or osteoarthritis. Additionally, Kenalog-40 can be effective in treating certain skin diseases such as psoriasis or eczema, as well as blood disorders, endocrine problems, and inflammatory eye conditions. Because it affects the immune response, it is often utilized when other treatments have not provided sufficient relief for systemic or localized inflammation.

Copay & patient assistance

Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program for more details.

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for TRIAMVEX. Official source: DailyMed (NLM) · Label effective Jul 9, 2025

Indications and usage
INDICATIONS & USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Dosage and administration
DOSAGE & ADMINISTRATION Topical corticosteroids are generally applied to the affected area as a thin film two to four times daily for the 0.025% strength and two or three times daily for the 0.1% and 0.5% strength depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Contraindications
CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Adverse reactions
ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
Use in pregnancy
PREGNANCY CATEGORY C Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How TRIAMVEX appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-04-30).

Covered by plans

73%

4,016 of 5,509 plans

Most common tier

Tier 2

On 50% of covering formularies

Prior authorization required

0%

of covering formularies

TierFormularies on this tierShare
Tier 1 (preferred generic)157
48%
Tier 2 (generic)161
50%
Tier 3 (preferred brand)5
2%
Tier 62
1%

Step therapy: 0% of formularies

Quantity limits: 47% of formularies

Coverage breadth: 325 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

PayerPAStep therapyCopay tier

Medicare Part D

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.